JPMorgan Chase & Co. set a GBX 5,500 ($77.12) price objective on AstraZeneca (LON:AZN) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently commented on the company. UBS Group set a GBX 4,550 ($63.80) price objective on AstraZeneca and gave the company a neutral rating in a research note on Tuesday, February 6th. Kepler Capital Markets raised their price objective on AstraZeneca from GBX 5,250 ($73.61) to GBX 5,300 ($74.31) and gave the company a buy rating in a research note on Tuesday, February 6th. Goldman Sachs Group set a GBX 3,800 ($53.28) price objective on AstraZeneca and gave the company a sell rating in a research note on Monday, February 5th. Credit Suisse Group reissued an outperform rating and issued a GBX 5,800 ($81.32) price objective on shares of AstraZeneca in a research note on Monday, February 5th. Finally, Barclays reissued a top pick rating and issued a GBX 6,300 ($88.33) price objective on shares of AstraZeneca in a research note on Monday, February 5th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. AstraZeneca has a consensus rating of Hold and an average target price of GBX 5,211.65 ($73.07).
Shares of AstraZeneca (LON:AZN) opened at GBX 4,770 ($66.88) on Thursday. AstraZeneca has a one year low of GBX 4,260 ($59.73) and a one year high of GBX 5,520 ($77.40). The company has a market capitalization of $60,260.00 and a P/E ratio of 2,805.88.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.